Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-07-10 Regulatory Filings
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206
Regulatory Filings Classification · 95% confidence The document is a press release dated July 10, 2025, announcing a corporate update regarding the completion of patient enrollment for a clinical study (FYB206 biosimilar candidate). It details study progress, regulatory interactions (FDA), expected result timelines (Q1 2026), and provides general company information. This type of announcement, focusing on operational milestones and clinical progress rather than formal periodic financial results (like 10-K or IR) or specific shareholder actions (like DEF 14A or DVA), is best classified as a general corporate news release. Since it is not a formal regulatory filing like a 10-K, nor a specific financial report, and it is not merely announcing the publication of another report (RPA), the most appropriate general category for significant, non-financial operational news that doesn't fit other specific codes is 'Regulatory Filings' (RNS) as a broad category for corporate disclosures, or potentially 'LTR' if it were about legal proceedings, but here it is about clinical development. Given the options, and that it is a general corporate news item disseminated via EQS News, RNS serves as the best fit for a non-standard, material corporate announcement that isn't a core financial report or management change.
2025-07-10 English
Bio Usawa becomes partner for the commercialization of FYB201/ BioUcentaTM (ranibizumab) across Sub-Saharan Africa
M&A Activity Classification · 99% confidence The document is a press release dated July 1, 2025, announcing a commercialization partnership between Formycon AG (via its licensee Bioeq AG) and Bio Usawa for the drug FYB201/BioUcenta™ across Sub-Saharan Africa. It details the terms of the agreement, product information, and market outlook. This type of announcement, which details strategic business developments, partnerships, or market access agreements, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, POS). It is a general corporate news announcement. Since it is not a formal regulatory filing like a 10-K or a specific report like an AR or CT, and it is not announcing the release of another report (RPA), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous corporate news releases that don't fit elsewhere.
2025-07-01 English
Formycon increases bond volume following oversubscription Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Capital/Financing Update Classification · 99% confidence The document is a press release dated June 27, 2025, announcing that Formycon AG successfully placed its corporate bond (2025/2029) for EUR 70 million following oversubscription. Key phrases include 'increases bond volume,' 'successfully and entirely placed,' 'offering period,' 'interest rate fixed,' and 'Inclusion to trading.' This content directly relates to the issuance of debt and capital market activities. Based on the provided definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP), as it details the successful completion of a bond issuance, which is a form of financing activity.
2025-06-27 English
Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany
Regulatory Filings Classification · 95% confidence The document is a press release dated June 26, 2025, announcing a commercialization partnership between Formycon AG and Teva's subsidiary Ratiopharm for a biosimilar drug (FYB202/Fymskina®) in Germany. It details business agreements, product launch timelines, and financial arrangements (milestone payments and margin share). This type of announcement, which details strategic business developments, partnerships, and commercial agreements, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). Since it is a general corporate news release disseminated via EQS News, and it is not announcing the *publication* of a major report (RPA) but rather the substance of a business deal, the most appropriate general category is Regulatory Filings (RNS), which serves as the fallback for miscellaneous corporate announcements that are not covered by more specific codes.
2025-06-26 English
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycons Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada
Regulatory Filings Classification · 100% confidence The document is a press release dated June 25, 2025, announcing a commercialization partnership between Formycon AG and Valorum Biologics LLC regarding a biosimilar drug (FYB203/AHZANTIVE®) for the US and Canada markets. It details financial arrangements (upfront payments, milestones, royalties) and strategic implications. This type of announcement, which details a significant business transaction, partnership, or strategic development, is not explicitly covered by the core financial report types (10-K, IR, ER). It is a general corporate news item disseminated via EQS News. Since it is not a specific regulatory filing like a Director's Dealing (DIRS), a Dividend Notice (DIV), or a Capital Change (CAP), and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is the Regulatory Filings/Miscellaneous category, RNS, as it is a broad announcement of corporate activity.
2025-06-25 English
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the early closing of the subscription period for Formycon AG's 2025/2029 corporate bond due to strong demand. It details the terms of the bond, the subscription deadlines, and the planned listing date. Crucially, the document explicitly states: 'THIS DOCUMENT IS NOT A PROSPECTUS BUT A PROMOTIONAL DOCUMENT; INVESTORS SHOULD SUBSCRIBE FOR OR PURCHASE THE SECURITIES REFERRED TO IN THIS PROMOTIONAL DOCUMENT SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS.' This indicates it is an announcement related to a financing activity (issuance of debt/bond) rather than the final comprehensive report (like 10-K or IR). The content directly relates to fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-06-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.